Guardant Health, Inc.
25
7
9
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.0%
2 terminated/withdrawn out of 25 trials
81.8%
-4.7% vs industry average
4%
1 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
Screening for High Frequency Malignant Disease
Role: lead
Guardant Shield Colorectal Cancer Screening
Role: collaborator
Shield Post-Approval Study Protocol
Role: lead
Understanding Patient Preference on Colorectal Cancer Screening Options-PSU
Role: collaborator
Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice Highlands
Role: collaborator
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Role: collaborator
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Role: lead
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Role: lead
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Role: lead
Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)
Role: collaborator
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
Role: collaborator
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
Role: collaborator
Biomarkers for Risk Stratification in Lung Cancer
Role: collaborator
Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients
Role: collaborator
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
Role: collaborator
Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")
Role: collaborator
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC
Role: collaborator
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
Role: lead
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
Role: collaborator
Noninvasive vs. Invasive Lung Evaluation
Role: lead